Clinical Trials Logo

Fibrous Histiocytoma clinical trials

View clinical trials related to Fibrous Histiocytoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06387485 Recruiting - Osteosarcoma Clinical Trials

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across 3 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, utilizing 3D printed models and imaging, or the active comparator arm, using only imaging. Primary endpoint: Operative time of surgical procedure. Secondary endpoints: Reduction of blood loss, proportion of postoperative adverse events, and negative tumor margins. Exploratory endpoints: Surgical planning ease, changes in surgical plan, and surgeon satisfaction.

NCT ID: NCT00356031 Recruiting - Soft Tissue Sarcoma Clinical Trials

Bevacizumab and Radiation Therapy for Sarcomas

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation.